In this video, we will delve into the world of topoisomerase inhibitors, exploring their role in cancer treatment. We will discuss what topoisomerase is, the difference between topoisomerase I and II, and why inhibitors are crucial in halting cancer cell growth. We will also spotlight the commonly used topoisomerase 1 inhibitor, irinotecan, and its mechanism of action. Additionally, we will dissect the notable side effects of irinotecan, particularly focusing on diarrhea and which patients should be wary of potential complications. Furthermore, we will touch on topoisomerase2 inhibitors like etoposide, their side effects, and their application in specific types of cancer such as leukemia and small cell lung cancer. Join us to understand how these inhibitors work in the cell cycle and their impact on cancer cells. Subscribe for more educational content on medical treatments and breakthroughs in cancer research.
#dnareplication #cancertreatment #chemotherapy

【Notes】
▹This video was created based on data as of March 2024, with the purpose of supporting medical students in their exam preparations.

▹Please note that thanks to the tireless efforts of researchers worldwide, this data is updated daily. ▹Unauthorized reproduction is prohibited.

【Contents】
00:00 topoisomerase?
00:30 topoisomerase inhibitors are used for cancer, why?
00:46 topoisomeraseI inhibitor, irinotecan
00:55 mechanism of action/ side effects of irinotecan
02:25 UGT1A1 mutation and irinotecan
02:47 topoisomeraseII inhibitor, etoposide
03:37 cell cycle and topoisomerase inhibitors

【Reference and figure】 I express my gratitude and respect for your wonderful achievements.

1. Buzun K, Bielawska A, Bielawski K, Gornowicz A. DNA topoisomerases as molecular targets for anticancer drugs. J Enzyme Inhib Med Chem. 2020 Dec;35(1):17811799. doi: 10.1080/14756366.2020.1821676. PMID: 32975138; PMCID: PMC7534307.

2. Nitiss JL, Soans E, Rogojina A, Seth A, Mishina M. Topoisomerase assays. Curr Protoc Pharmacol. 2012 Jun;Chapter 3:Unit 3.3.. doi: 10.1002/0471141755.ph0303s57. PMID: 22684721; PMCID: PMC3397423.

3. Balraj Mittal, Sonam Tulsyan, Surendra Kumar, Rama Devi Mittal, Gaurav Agarwal, Chapter Four Cytochrome P450 in Cancer Susceptibility and Treatment, Editor(s): Gregory S. Makowski, Advances in Clinical Chemistry, Elsevier, Volume 71, 2015, Pages 77139, ISSN 00652423, ISBN 9780128022566,
https://doi.org/10.1016/bs.acc.2015.0....
(https://www.sciencedirect.com/science...)

4. Stein A, Voigt W, Jordan K. Chemotherapyinduced diarrhea: pathophysiology, frequency and guidelinebased management. Ther Adv Med Oncol. 2010 Jan;2(1):5163. doi: 10.1177/1758834009355164. PMID: 21789126; PMCID: PMC3126005.

5. Godefridus J. Peters, Chapter 1 Drug resistance in colorectal cancer: General aspects, Editor(s): Chi Hin Cho, Tao Hu, In Cancer Sensitizing Agents for Chemotherapy, Drug Resistance in Colorectal Cancer: Molecular Mechanisms and 6. Therapeutic Strategies, Academic Press, Volume 8, 2020, Pages 133, ISSN 24683183, ISBN 9780128199374,
https://doi.org/10.1016/B978012819....
(https://www.sciencedirect.com/science...)

7. PubChem, Irinotecan|C33H38N4O6|CID6838, Etoposide|C29H32O13|CID36462

8. McNamee N, da Silva IP, Nagrial A, Gao B. SmallCell Lung CancerAn Update on Targeted and Immunotherapies. Int J Mol Sci. 2023 May 1;24(9):8129. doi: 10.3390/ijms24098129. PMID: 37175833; PMCID: PMC10179261.

9. Abe Y, Tanaka N. The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy. Biomed Res Int. 2016;2016:7969286. doi: 10.1155/2016/7969286. Epub 2016 Dec 26. PMID: 28105432; PMCID: PMC5220431.

10. Dr. Parth Desai, National Cancer Institute, Smallcell lung carcinoma cells under the microscope.
Targeted treatments for smallcell lung cancer, NIH Research Matters, April 27, 2021.
https://www.nih.gov/newsevents/nihr...

11. Lee JH, Berger JM. Cell CycleDependent Control and Roles of DNA Topoisomerase II. Genes (Basel). 2019 Oct 30;10(11):859. doi: 10.3390/genes10110859. PMID: 31671531; PMCID: PMC6896119.